Mehmet Yildiz
Mehmet Yildiz has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Hasan Selçuk Özger
Koç University Faculty of Medicine, Department of Infectious Diseases, İstanbul, Türkiye
5 shared publications - Murat Dizbay
Gazi Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Ankara, Turkiye
5 shared publications - Nazlıhan Boyacı Dündar
Department of Internal Medicine, Division of Intensive Care Medicine, Gazi University School of Medicine, Ankara, Türkiye
3 shared publications - Pınar Aysert Yıldız
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara 06500, Türkiye
3 shared publications - Özlem Güzel Tunçcan
Gazi Üniversitesi Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Ankara
3 shared publications - Ümmügülsüm Gaygısız
Department of Anesthesiology and Reanimation, Division of Intensive Care Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
3 shared publications
Latest Publications
- 31 August 2026
- Published by Springer Nature in Infection
- p. 1-8
Clinical utility of time to positivity in candidemia: prognostic limitations and species-specific implications
- 31 August 2026
- Published by Springer Nature in Infection
- p. 1-8
Clinical utility of time to positivity in candidemia: prognostic limitations and species-specific implications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 68
Septic arthritis caused by Nocardia asiatica: a case report and narrative review
Nocardia asiatica is a rare opportunistic pathogen typically associated with pulmonary and central nervous system infections; however, musculoskeletal infections are uncommon. We report a case of septic arthritis caused by N. asiatica in a 72-year-old man with a history of chronic obstructive pulmonary disease (COPD) and pneumoconiosis. The patient presented with subacute knee swelling following a recent episode of pneumonia. Gram staining of intraoperative synovial samples revealed branching filamentous organisms, and the isolate was identified as N. asiatica by mass spectrometry. Although the patient was transferred to another center during the initial phase of management, follow-up information obtained after discharge confirmed a favorable clinical recovery without recurrence. Our report contributes to the limited literature on the clinical manifestations, organ tropism, and antimicrobial susceptibility patterns associated with N. asiatica infection.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 68
Open AccessSeptic arthritis caused by Nocardia asiatica: a case report and narrative review
Nocardia asiatica is a rare opportunistic pathogen typically associated with pulmonary and central nervous system infections; however, musculoskeletal infections are uncommon. We report a case of septic arthritis caused by N. asiatica in a 72-year-old man with a history of chronic obstructive pulmonary disease (COPD) and pneumoconiosis. The patient presented with subacute knee swelling following a recent episode of pneumonia. Gram staining of intraoperative synovial samples revealed branching filamentous organisms, and the isolate was identified as N. asiatica by mass spectrometry. Although the patient was transferred to another center during the initial phase of management, follow-up information obtained after discharge confirmed a favorable clinical recovery without recurrence. Our report contributes to the limited literature on the clinical manifestations, organ tropism, and antimicrobial susceptibility patterns associated with N. asiatica infection.
- Open Access
- 26 September 2024
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 6 (3) , 206-215
Changes of Procalcitonin Kinetics According to Renal Clearance in Critically Ill Patients with Primary Gram-Negative Bloodstream Infections
Procalcitonin (PCT) is a biomarker frequently used in the diagnosis and prognosis of infection. The lack of optimum cut-off values and the high serum PCT levels in some non-infectious conditions restrict its clinical use. Therefore, PCT use is not recommended regardless of clinical parameters. This limitation in clinical use has led to PCT kinetic evaluations rather than predictions
- 26 September 2024
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 6 (3) , 206-215
Open AccessChanges of Procalcitonin Kinetics According to Renal Clearance in Critically Ill Patients with Primary Gram-Negative Bloodstream Infections
Procalcitonin (PCT) is a biomarker frequently used in the diagnosis and prognosis of infection. The lack of optimum cut-off values and the high serum PCT levels in some non-infectious conditions restrict its clinical use. Therefore, PCT use is not recommended regardless of clinical parameters. This limitation in clinical use has led to PCT kinetic evaluations rather than predictions
- Open Access
- 29 August 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-9
The effect of follow-up blood cultures on mortality and antibiotic use in gram-negative bloodstream infections
Background: Gram-negative bloodstream infections (GN-BSIs) are a significant clinical challenge. The utility of follow-up blood cultures (FUBCs) in GN-BSIs and their impact on mortality and antibiotic consumption are areas of debate. This study aimed to evaluate the effect of FUBCs on mortality and antibiotic consumption in patients with GN-BSIs. Methods: This single-center, retrospective study was conducted in aged > 18 years of patients with GN-BSIs. FUBC was defined as a blood culture performed 2–7 days after the first blood culture. Patients were grouped as FUBC and no FUBC and compared. A 1:1 match analysis was performed between the groups according to the SOFA score. The matched subgroup was compared for mortality risk factors with logistic regression models. The two groups were compared for the duration of effective antibiotic therapy and total antibiotic consumption (days of therapy per 1000 patient days (DOT/1000 PD)). Results: FUBC was performed in 564 (69.4%) of 812 patients. Persistent, positive and negative FUBC rates were 7.9%, 14%, and 78%, respectively. The frequency of persistent GN-BSI in patients with appropriate antibiotic therapy was 3.9%. SOFA score (OR:1.33; 95% CI, 1.23–1.44), Charlson comorbidity index score (OR:1.18; 95% CI, 1.08–1.28), hospital-acquired infections (OR:1.93; 95% CI, 1.08–3.46) and carbapenem-resistant GN-BSI (OR: 2.92; 95% CI, 1.72–4.96) were independent risk factors for mortality. No relationship was found between FUBC and mortality (p > 0.05). Duration of effective antibiotic therapy (10(4–16) vs. 15(9–20), p < 0.001) and DOT/1000 PD (1609 (1000–2178) vs. 2000 (1294–2769), p < 0.001) were longer in the FUBC group. Conclusion: Routine FUBC should not be recommended because of the low prevalence of persistent infections in patients under appropriate antibiotic therapy and FUBC increases antibiotic consumption.
- 29 August 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-9
Open AccessThe effect of follow-up blood cultures on mortality and antibiotic use in gram-negative bloodstream infections
Background: Gram-negative bloodstream infections (GN-BSIs) are a significant clinical challenge. The utility of follow-up blood cultures (FUBCs) in GN-BSIs and their impact on mortality and antibiotic consumption are areas of debate. This study aimed to evaluate the effect of FUBCs on mortality and antibiotic consumption in patients with GN-BSIs. Methods: This single-center, retrospective study was conducted in aged > 18 years of patients with GN-BSIs. FUBC was defined as a blood culture performed 2–7 days after the first blood culture. Patients were grouped as FUBC and no FUBC and compared. A 1:1 match analysis was performed between the groups according to the SOFA score. The matched subgroup was compared for mortality risk factors with logistic regression models. The two groups were compared for the duration of effective antibiotic therapy and total antibiotic consumption (days of therapy per 1000 patient days (DOT/1000 PD)). Results: FUBC was performed in 564 (69.4%) of 812 patients. Persistent, positive and negative FUBC rates were 7.9%, 14%, and 78%, respectively. The frequency of persistent GN-BSI in patients with appropriate antibiotic therapy was 3.9%. SOFA score (OR:1.33; 95% CI, 1.23–1.44), Charlson comorbidity index score (OR:1.18; 95% CI, 1.08–1.28), hospital-acquired infections (OR:1.93; 95% CI, 1.08–3.46) and carbapenem-resistant GN-BSI (OR: 2.92; 95% CI, 1.72–4.96) were independent risk factors for mortality. No relationship was found between FUBC and mortality (p > 0.05). Duration of effective antibiotic therapy (10(4–16) vs. 15(9–20), p < 0.001) and DOT/1000 PD (1609 (1000–2178) vs. 2000 (1294–2769), p < 0.001) were longer in the FUBC group. Conclusion: Routine FUBC should not be recommended because of the low prevalence of persistent infections in patients under appropriate antibiotic therapy and FUBC increases antibiotic consumption.
- Open Access
- 21 February 2022
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 2 (1) , e30
Evaluation of prevalance and risk factors for bloodstream infection in severe coronavirus disease 2019 (COVID-19) patients
Objectives: In this study, we sought to determine the prevalence of bloodstream infection (BSI) in severe coronavirus disease 2019 (COVID-19) patients and to determine the risk factors of BSI in critical COVID-19 patients. Design: Retrospective, descriptive study between March 2020 and January 2021. Setting: An 1,007-bed university hospital. Participants: Patients who were hospitalized due to severe COVID-19 disease and had an aerobic blood culture taken at least once during hospitalization Methods: Case definitions were made according to National Institutes of Health clinical definitions. According to the blood culture results, the patients were grouped as with and without BSIs, and compared for BSIs risk factors. Results: In total, 195 patients were included in the study. Blood culture positivity was detected in 76 (39.0%) of 196 patients. Excluding blood culture positivity considered as contamination, the prevalence of BSI in all severe COVID-19 cases was 18.5% (n = 36). In intensive care unit patients the prevalence of BSI was 30.6% (n = 26). In multivariate analyses, central venous catheter (odds ratio [OR], 8.17; 95% confidence interval [CI], 2.46–27.1; P < .01) and hospitalization in the multibed intensive care unit (OR, 4.28; 95% CI, 1.28–14.3; P < .01) were risk factors associated with the acquisition of BSI. Conclusion: The prevalence of BSI in COVID-19 patients is particularly high in critically ill patients. The central venous catheter and multibed intensive care follow-up are risk factors for BSI. BSIs can be reduced by increasing compliance to infection control measures and central venous catheter insertion-care procedures. The use of single-bed intensive care units where compliance can be achieved more effectively is important for the prevention of BSIs.
- 21 February 2022
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 2 (1) , e30
Open AccessEvaluation of prevalance and risk factors for bloodstream infection in severe coronavirus disease 2019 (COVID-19) patients
Objectives: In this study, we sought to determine the prevalence of bloodstream infection (BSI) in severe coronavirus disease 2019 (COVID-19) patients and to determine the risk factors of BSI in critical COVID-19 patients. Design: Retrospective, descriptive study between March 2020 and January 2021. Setting: An 1,007-bed university hospital. Participants: Patients who were hospitalized due to severe COVID-19 disease and had an aerobic blood culture taken at least once during hospitalization Methods: Case definitions were made according to National Institutes of Health clinical definitions. According to the blood culture results, the patients were grouped as with and without BSIs, and compared for BSIs risk factors. Results: In total, 195 patients were included in the study. Blood culture positivity was detected in 76 (39.0%) of 196 patients. Excluding blood culture positivity considered as contamination, the prevalence of BSI in all severe COVID-19 cases was 18.5% (n = 36). In intensive care unit patients the prevalence of BSI was 30.6% (n = 26). In multivariate analyses, central venous catheter (odds ratio [OR], 8.17; 95% confidence interval [CI], 2.46–27.1; P < .01) and hospitalization in the multibed intensive care unit (OR, 4.28; 95% CI, 1.28–14.3; P < .01) were risk factors associated with the acquisition of BSI. Conclusion: The prevalence of BSI in COVID-19 patients is particularly high in critically ill patients. The central venous catheter and multibed intensive care follow-up are risk factors for BSI. BSIs can be reduced by increasing compliance to infection control measures and central venous catheter insertion-care procedures. The use of single-bed intensive care units where compliance can be achieved more effectively is important for the prevention of BSIs.
- 20 October 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (5) , 2296-2303
Assessment of olfactory and gustatory functions in COVID-19 patients
Background/aim: This study aims to evaluate of olfactory and gustatory functions of COVID-19 patients and possible risk factors for olfactory and gustatory dysfunctions. Materials and methods: The cross-sectional study included adult patients who were diagnosed with COVID-19 in Gazi University Hospital between April 2020 and June 2020. Volunteered patients participated in a survey in which olfactory and gustatory functions and various clinical information were questioned. Sinonasal Outcome Test-22 was also administrated to all patients. Results: A hundred and seventy-one patients participated in this study. Olfactory and gustatory dysfunctions rates were 10.5% (n: 18) and 10.5% (n: 18), respectively. Patients without any symptom other than smell and taste dysfunctions were clustered as group 1 and patients who are clinically symptomatic were clustered as group 2. Olfactory dysfunction occurred in 8% of group 1 and 17.4% of group 2 (p = 0.072). Gustatory dysfunction rate of smokers was 19.7% and significantly higher than gustatory dysfunction rate of nonsmokers (5.5%) (p = 0.007). Twenty-seven-point-eight percent of the patients with olfactory dysfunction (n = 5) were male and 72.2% (n: 13) were female. Sex did not show significant effect on rate of olfactory dysfunction. Twenty-five patients participated in psychophysical olfactory function test. No participant reported olfactory dysfunction at the time of test. Of the participants, 64% (n: 16) were normosmic and 36% (n: 9) were hyposmic according to Sniffin' Stick test. Conclusion: Olfactory and gustatory dysfunctions are more common in patients who are clinically symptomatic than those diagnosed during contact tracing. Objective tests may show that frequency of olfactory dysfunction is greater than frequency of self-reported olfactory dysfunction.
- 20 October 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (5) , 2296-2303
Assessment of olfactory and gustatory functions in COVID-19 patients
Background/aim: This study aims to evaluate of olfactory and gustatory functions of COVID-19 patients and possible risk factors for olfactory and gustatory dysfunctions. Materials and methods: The cross-sectional study included adult patients who were diagnosed with COVID-19 in Gazi University Hospital between April 2020 and June 2020. Volunteered patients participated in a survey in which olfactory and gustatory functions and various clinical information were questioned. Sinonasal Outcome Test-22 was also administrated to all patients. Results: A hundred and seventy-one patients participated in this study. Olfactory and gustatory dysfunctions rates were 10.5% (n: 18) and 10.5% (n: 18), respectively. Patients without any symptom other than smell and taste dysfunctions were clustered as group 1 and patients who are clinically symptomatic were clustered as group 2. Olfactory dysfunction occurred in 8% of group 1 and 17.4% of group 2 (p = 0.072). Gustatory dysfunction rate of smokers was 19.7% and significantly higher than gustatory dysfunction rate of nonsmokers (5.5%) (p = 0.007). Twenty-seven-point-eight percent of the patients with olfactory dysfunction (n = 5) were male and 72.2% (n: 13) were female. Sex did not show significant effect on rate of olfactory dysfunction. Twenty-five patients participated in psychophysical olfactory function test. No participant reported olfactory dysfunction at the time of test. Of the participants, 64% (n: 16) were normosmic and 36% (n: 9) were hyposmic according to Sniffin' Stick test. Conclusion: Olfactory and gustatory dysfunctions are more common in patients who are clinically symptomatic than those diagnosed during contact tracing. Objective tests may show that frequency of olfactory dysfunction is greater than frequency of self-reported olfactory dysfunction.
- 31 August 2021
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 3 (2) , 55-63
Effect of Tocilizumab Therapy On Patient Outcome In Severe COVID-19 Pneumonia
Background: This study aimed to evaluate the impact of tocilizumab treatment on clinical improvement in severe COVID-19 cases and the factors affecting clinical response. Methods: This single-center, retrospective, descriptive study was conducted on severe COVID-19 patients. The ordinal scale of clinical status scores on the 0th, 1st, 3rd, and 7th days of tocilizumab treatment was calculated and compared for each patient. The ordinal scale of clinical status scores calculated on different days for the same patient was compared with Wilcoxon tests. The correlation between the clinical score and some laboratory parameters was evaluated by Pearson correlation analysis. Patients were grouped as responders and non-responders and compared by logistic regression analysis. Results: Forty-two patients were enrolled in the study. The median of the ordinal scale of clinical status scores on the 0th, 1st, 3rd, and 7th days of tocilizumab treatment were 6 (5 to 6), 6 (5 to 6), 6 (5 to 6), and 5 (4 to 7), respectively. When the clinical status scores on the 0 to 7 days of tocilizumab treatment were compared, the difference was statistically significant (p = 0.024, Wilcoxon). There was no statistically significant difference between day 0 and day 1 (p=0.317, Wilcoxon), day 0 and day 3 (p=0.467, Wilcoxon). By multivariate analysis, we determined that age ( OR: 0.91, 95% 0.84-0.98) and respiratory rate (OR:0.78, 95% 0.62-0.98) were factors affecting the response of tocilizumab treatment. No relationship was detected between laboratory parameters before tocilizumab treatment, including IL-6 levels and clinical response (p=0.756, Mann Whitney-U). Conclusion: The use of tocilizumab in younger patients with low oxygen support increases the chance of clinical response after treatment. Since the effect of laboratory parameters in predicting the clinical response of tocilizumab is limited, treatment indications should be determined based on clinical parameters. Keywords: COVID-19, tocilizumab treatment, cytokine storm
- 31 August 2021
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 3 (2) , 55-63
Effect of Tocilizumab Therapy On Patient Outcome In Severe COVID-19 Pneumonia
Background: This study aimed to evaluate the impact of tocilizumab treatment on clinical improvement in severe COVID-19 cases and the factors affecting clinical response. Methods: This single-center, retrospective, descriptive study was conducted on severe COVID-19 patients. The ordinal scale of clinical status scores on the 0th, 1st, 3rd, and 7th days of tocilizumab treatment was calculated and compared for each patient. The ordinal scale of clinical status scores calculated on different days for the same patient was compared with Wilcoxon tests. The correlation between the clinical score and some laboratory parameters was evaluated by Pearson correlation analysis. Patients were grouped as responders and non-responders and compared by logistic regression analysis. Results: Forty-two patients were enrolled in the study. The median of the ordinal scale of clinical status scores on the 0th, 1st, 3rd, and 7th days of tocilizumab treatment were 6 (5 to 6), 6 (5 to 6), 6 (5 to 6), and 5 (4 to 7), respectively. When the clinical status scores on the 0 to 7 days of tocilizumab treatment were compared, the difference was statistically significant (p = 0.024, Wilcoxon). There was no statistically significant difference between day 0 and day 1 (p=0.317, Wilcoxon), day 0 and day 3 (p=0.467, Wilcoxon). By multivariate analysis, we determined that age ( OR: 0.91, 95% 0.84-0.98) and respiratory rate (OR:0.78, 95% 0.62-0.98) were factors affecting the response of tocilizumab treatment. No relationship was detected between laboratory parameters before tocilizumab treatment, including IL-6 levels and clinical response (p=0.756, Mann Whitney-U). Conclusion: The use of tocilizumab in younger patients with low oxygen support increases the chance of clinical response after treatment. Since the effect of laboratory parameters in predicting the clinical response of tocilizumab is limited, treatment indications should be determined based on clinical parameters. Keywords: COVID-19, tocilizumab treatment, cytokine storm
- Open Access
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1810-1816
The factors predicting pneumonia in COVID-19 patients: preliminary results from a university hospital in Turkey
Pneumonia is the most serious clinical presentation of COVID-19. This study aimed to determine the demographic, clinical, and laboratory findings that can properly predict COVID-19 pneumonia. This study was conducted in the Gazi University hospital. All hospitalized patients with confirmed and suspected SARS-CoV-2 infection between 16 March 2020 and 30 April 2020 were analyzed retrospectively. COVID-19 patients were separated into two groups, pneumonia and nonpneumonia, and then compared to determine predicting factors for COVID-19 pneumonia. Variables that had a P-value of less than 0.20 and were not correlated with each other were included in the logistic regression model. Of the 247 patients included in the study 58% were female, and the median age was 40. COVID-19 was confirmed in 70.9% of these patients. Among the confirmed COVID-19 cases, 21.4% had pneumonia. In the multivariate analysis male sex (P = 0.028), hypertension (P = 0.022), and shortness of breath on hospital admission (P = 0.025) were significant factors predicting COVID-19 pneumonia. Shortness of breath, male sex, and hypertension were significant for predicting COVID-19 pneumonia on admission. Patients with these factors should be evaluated more carefully for diagnostic procedures, such as thorax CT.
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1810-1816
Open AccessThe factors predicting pneumonia in COVID-19 patients: preliminary results from a university hospital in Turkey
Pneumonia is the most serious clinical presentation of COVID-19. This study aimed to determine the demographic, clinical, and laboratory findings that can properly predict COVID-19 pneumonia. This study was conducted in the Gazi University hospital. All hospitalized patients with confirmed and suspected SARS-CoV-2 infection between 16 March 2020 and 30 April 2020 were analyzed retrospectively. COVID-19 patients were separated into two groups, pneumonia and nonpneumonia, and then compared to determine predicting factors for COVID-19 pneumonia. Variables that had a P-value of less than 0.20 and were not correlated with each other were included in the logistic regression model. Of the 247 patients included in the study 58% were female, and the median age was 40. COVID-19 was confirmed in 70.9% of these patients. Among the confirmed COVID-19 cases, 21.4% had pneumonia. In the multivariate analysis male sex (P = 0.028), hypertension (P = 0.022), and shortness of breath on hospital admission (P = 0.025) were significant factors predicting COVID-19 pneumonia. Shortness of breath, male sex, and hypertension were significant for predicting COVID-19 pneumonia on admission. Patients with these factors should be evaluated more carefully for diagnostic procedures, such as thorax CT.